By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DV Biologics and System Biosciences this week announced a partnership to develop human-derived, disease-specific induced pluripotent stem cell lines.

Under the terms of the deal, System Biosciences will convert many of DV Biologics' disease-specific cell types into iPSCs, using its proprietary products for reprogramming and iPSC generation, the two firms said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.